Physician profile
Arthur Badillo
NPI 1770635484
$6,385.40
in general payments reported to CMS, 2019-2025
34 companies · $63.24 in 2025
The $63.24 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,700 · 2020: $1,363 · 2021: $1,420 · 2022: $1,130 · 2023: $443 · 2024: $266 · 2025: $63.24.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $772.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $772.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,188.55 | 2019-2024 | Ozempic, Rybelsus |
| Lilly USA, LLC | $767.71 | 2019-2024 | Jardiance, Mounjaro |
| Sanofi-Aventis U.S. LLC | $676.53 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $568.37 | 2019-2023 | Belsomra |
| Glaxosmithkline, LLC. | $552.80 | 2019-2024 | Trelegy Ellipta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $402.19 | 2019-2025 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $380.38 | 2019-2024 | Breztri, Farxiga, Airsupra |
| Amarin Pharma, INC. | $235.69 | 2020-2021 | |
| Amgen INC. | $229.80 | 2019-2024 | Otezla, Repatha |
| Abiomed | $161.64 | 2023 | Impella |
| Bard Peripheral Vascular, INC. | $144.02 | 2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $142.50 | 2021-2022 | |
| Kowa Pharmaceuticals America, INC. | $110.23 | 2019-2021 | |
| Abbott Laboratories | $101.71 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $91.78 | 2019-2022 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Angiodynamics, INC. | $73.30 | 2021 | |
| Horizon Therapeutics Plc | $69.84 | 2020-2022 | |
| E.R. Squibb & Sons, L.L.C. | $58.66 | 2019-2023 | Eliquis |
| Abbvie INC. | $56.01 | 2021 | |
| Allergan, INC. | $52.64 | 2020 | |
| Pfizer INC. | $50.25 | 2019-2022 | |
| Esperion Therapeutics, INC. | $39.89 | 2020 | |
| Arbor Pharmaceuticals, INC. | $35.07 | 2019-2020 | |
| Scilex Pharmaceuticals INC. | $26.26 | 2022 | |
| Novartis Pharmaceuticals Corporation | $25.62 | 2021-2022 | |
| Dexcom, INC. | $23.04 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $17.50 | 2023 | Rexulti |
| Becton, Dickinson and Company | $16.88 | 2022 | |
| Xeris Pharmaceuticals, INC. | $16.60 | 2023 | Gvoke Hypopen |
| Phathom Pharmaceuticals, INC. | $15.29 | 2024 | Voquezna |
| Genentech USA, INC. | $15.00 | 2019 | |
| Nabriva Therapeutics, Plc | $13.74 | 2021 | |
| Renalytix Ai, INC. | $13.66 | 2024 | Kidneyintelx Blood Collection Convenience Kit |
| Astellas Pharma US INC | $12.25 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Arthur Badillo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.